Biohaven (NYSE:BHVN) Raised to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Biohaven from “Sell” to “Hold.” Despite mixed analyst views, the stock carries a broader “Moderate Buy” consensus with an average price target of $19.25.
• Biohaven shares opened at $13.89, with a market capitalization of approximately $2.1 billion. The company remains unprofitable and recently reported a quarterly loss of $0.91 per share, below the $0.76-per-share consensus estimate.
• Institutional investors own 88.78% of Biohaven’s stock, with several funds increasing their positions. Investor interest has also been supported by the FDA’s acceptance of the company’s resubmitted Vyglxia application for review, although approval is not guaranteed.

Biohaven (NYSE:BHVN - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

BHVN has been the subject of several other reports. TD Cowen restated a "buy" rating on shares of Biohaven in a research report on Wednesday, August 26th. Royal Bank Of Canada boosted their target price on shares of Biohaven from $19.00 to $22.00 and gave the company a "sector perform" rating in a research note on Friday. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Biohaven in a research report on Friday, August 28th. Raymond James Financial restated a "strong-buy" rating on shares of Biohaven in a research report on Thursday, October 8th. Finally, Needham & Company LLC set a $11.00 price target on shares of Biohaven in a report on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $19.25.

Biohaven Stock Performance

Biohaven stock opened at $13.89 on Friday. Biohaven has a 1-year low of $7.48 and a 1-year high of $18.57. The firm has a market cap of $2.10 billion, a P/E ratio of -2.99 and a beta of 1.35. The firm has a 50-day moving average of $13.51 and a 200-day moving average of $12.70. The company has a current ratio of 4.73, a quick ratio of 4.73 and a debt-to-equity ratio of 21.23.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). Sell-side analysts expect that Biohaven will post -3.33 EPS for the current year.

Institutional Investors Weigh In On Biohaven

Several hedge funds and other institutional investors have recently made changes to their positions in BHVN. The Manufacturers Life Insurance Company grew its holdings in shares of Biohaven by 52.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 202,975 shares of the company's stock valued at $1,717,000 after purchasing an additional 69,894 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Biohaven during the first quarter valued at approximately $1,362,000. Janus Henderson Group PLC boosted its holdings in Biohaven by 1,145.9% in the first quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company's stock worth $148,214,000 after acquiring an additional 16,127,247 shares in the last quarter. Quantinno Capital Management LP raised its stake in shares of Biohaven by 190.0% during the 1st quarter. Quantinno Capital Management LP now owns 121,554 shares of the company's stock valued at $1,028,000 after buying an additional 79,640 shares during the last quarter. Finally, NewEdge Wealth LLC acquired a new stake in shares of Biohaven in the second quarter valued at about $3,656,000. 88.78% of the stock is owned by institutional investors.

Key Headlines Impacting Biohaven

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: FDA review removes a key regulatory hurdle. The FDA accepted Biohaven’s resubmitted application, meaning the agency will conduct a formal review of Vyglxia. A regulatory decision is expected in the first quarter of 2027. Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
• Positive Sentiment: Investors are reassessing the drug’s commercial potential. Coverage highlighted the possibility that approval could give Biohaven a significant new growth opportunity in a rare neurological disease, helping explain the stock’s unusually large advance and some analyst price-target increases. Biohaven Soars 25% on FDA Drug Review, Price Target Upgrade
• Positive Sentiment: Trading activity reinforced the bullish move. Investors purchased 6,072 BHVN call options, approximately 155% above typical daily call volume, signaling heightened speculative interest in further upside. Why Biohaven catapulted 30%-plus and why it might not be done sprinting
• Neutral Sentiment: The FDA has accepted the application for review—not approved Vyglxia. The upcoming review creates a major catalyst, but the outcome remains uncertain and the company still faces the time and expense of completing the regulatory process. Biohaven Stock Soars As FDA Accepts Vyglyxia Resubmission
• Negative Sentiment: Sharp gains increase volatility and profit-taking risk. The stock’s rally appears driven largely by a single regulatory event and options activity, while Biohaven remains an unprofitable biotech. Any negative FDA feedback, delay, or questions about Vyglxia’s efficacy or market opportunity could reverse the move.

Biohaven Company Profile

Biohaven Ltd. NYSE: BHVN is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company's research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven's pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.